Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent colitis and using human in vitro inflammation models. Its use as a food ingredient has proven safe and with no influence on dietary intake. We hypothesize that orally administered CGMP has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Arla Foods
• Treatments: Caseins; Mesalamine

Criteria

Inclusion Criteria:

• Age 18 years or more

• Diagnosed ulcerative colitis

• Signs of clinical activity with SCCAI of 3 or more

• Extension more than 10 cm and no more than 40 cm from anus

Exclusion Criteria:

• Rectal temperature more than 38 degrees Celcius

• Diagnosed celiac disease or lactose intolerance

• Unable to speak or understand Danish

• Prior biologics or systemic steroids 4 weeks up to inclusion